NCT06017284View on ClinicalTrials.gov

Thalidomide to Chemotherapy Related Nausea and Vomiting in Pancreatic Cancer

PHASE3RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

November 1, 2023

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2026

Conditions
Pancreatic Cancer Stage IVChemotherapy-induced Nausea and Vomiting
Interventions
DRUG

Thalidomide

Thalidomide 100 mg/day, once a day, orally intake at night.

DRUG

Nab paclitaxel

nab-paclitaxel (120 mg per square meter of body-surface area) on days 1, 8, and 15 every 4 weeks.

DRUG

Gemcitabine

gemcitabine (1000 mg per square meter) on days 1, 8, and 15 every 4 weeks.

DRUG

Placebo

Placebo, 100 mg/day, once a day, orally intake at night.

Trial Locations (1)

200032

RECRUITING

Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER